Surge In Viral Infections Driving Growth Of The Market Due To Increasing Disease Prevalence And Diagnostic Needs: An Emerging Driver Transforming The Exanthema Market Landscape

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Projected Growth of the Exanthema Market?
In recent years, there has been a steady growth in the exanthema market size. The market is projected to increase from $2.18 billion in 2024 to $2.28 billion in 2025, accruing a compound annual growth rate (CAGR) of 4.7%. Reasons contributing to this growth during the historical period include higher healTH*Care spending, greater public awareness about vaccinations, an increase in disposable income, growing understanding of skin diseases, and a heightened focus on early detection.

In the coming years, a consistent rise is predicted in the size of the exanthema market. By 2029, it is projected to reach $2.71 billion, experiencing a compound annual growth rate (CAGR) of 4.4%. This growth during the projected period can be linked to the escalating investments made in research and development, an increase in viral and bacterial infection cases, the burgeoning influence of telemedicine, more initiatives by the government, and the growing demand for oral medication. Significant trends forecasted for this period are improvements in treatment methodologies, new innovations in diagnostic procedures, technological progress, development in medical research and technology, and supportive technologies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21962

What Are the Different Exanthema Market Segments?
The exanthema market covered in this report is segmented -

1) By Types: Bacterial, Viral, Other Types
2) By Treatment: Topical Treatments, Systemic Treatments, Supportive Care
3) By Diagnosis Method: Clinical Examination, Laboratory Tests, Imaging Techniques
4) By Application: Rubeola, Rubella, Erythema Infectiosum, Roseola Infantum
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Bacterial Exanthema: Scarlet Fever, Meningococcemia, Staphylococcal Scalded Skin Syndrome (SSSS), Lyme Disease, Tuberculosis-Associated Exanthema
2) By Viral Exanthema: Measles (Rubeola), Rubella (German Measles), Varicella (Chickenpox), Roseola (Exanthem Subitum), Hand, Foot, and Mouth Disease, Parvovirus B19 (Erythema Infectiosum / Fifth Disease), Dengue Fever Rash, Zika Virus Rash
3) By Other Types of Exanthema: Drug-Induced Exanthema (Hypersensitivity Reactions), Autoimmune-Related Exanthema (Lupus, Kawasaki Disease), Allergic Dermatitis-Related Exanthema, Fungal Infections Leading to Exanthema, Environmental and Toxin-Induced Exanthema

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21962&type=smp

What Are the Primary Drivers Shaping the Exanthema Market?
The augmenting occurrence of viral infections is anticipated to fuel the advancement of the exanthema market. Viral infections imply ailments precipitated by viruses infringing and multiplying inside the body's cells, consequently causing various symptoms and diseases. Incrementing global travel, urbanization, climate change and compromised immunity are key factors contributing to the rise of viral infections. This escalation in viral infections amps up the requirement for exanthema treatments as the number of cases reporting skin rashes escalate, thereby increasing the demand for effective control. Exanthema acts as an observable immune response to these viral infections, assisting in evicting pathogens, signaling immune initiation and supporting diagnosis by denoting the body's combat against the virus. For instance, as per data from the Centers for Disease Control and Prevention, a US government agency, during 2022-2024, the population percentage with IgM antibodies (indicating a recent Parvovirus B19 infection), stayed below 3% but escalated to 10% by June 2024. The most profound increase was noted among children aged 5-9 years, where prevalence escalated from 15% to 40% during the said period. Hence, the burgeoning occurrence of viral infections is catalyzing the growth of the exanthema market.

Which Companies Are Leading in the Exanthema Market?
Major companies operating in the exanthema market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Abbott Laboratories, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., Daiichi Sankyo Company Limited, Biological E. Limited, Zydus Lifesciences Limited, Bio Farma, Meridian Bioscience Inc., West-Ward Pharmaceutical Corp., Trinity Biotech plc, Biosynth Srl, Creative Diagnostics, Taj Pharmaceuticals Limited, TestLine Clinical Diagnostics s.r.o., The Native Antigen Co. Ltd., QED Bioscience Inc.

What Are the Major Trends Shaping the Exanthema Market?
Key exanthema market players are increasingly adopting innovative therapies such as administering vaccines and antiviral treatments intramuscularly to enhance efficacy, minimize complications, and optimize patient prognosis for exanthematous-related viral infections. Intramuscular (IM) administration of antiviral treatments and vaccines involves direct injections into the muscle using a syringe and needle, ensuring swift absorption into the bloodstream by utilizing the muscles' rich blood supply to elicit an immune response or treatment effect. To illustrate, in March 2023, the US-based pharmaceutical firm, Merck & Co. Inc., reported that the FDA sanctioned the IM administration mechanism for its MMRV vaccines-M-M-R II, VARIVAX, and ProQuad. The IM method is widely recognized for providing increased stability and efficiency for these live-virus vaccines in comparison to other administration techniques, hence playing a vital role in augmenting public healTH*Care strategies to thwart these potentially serious viral infections.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/exanthema-global-market-report

What Are the Top Revenue-Generating Geographies in the Exanthema Market?
North America was the largest region in the exanthema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exanthema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Exanthema Market?
2. What is the CAGR expected in the Exanthema Market?
3. What Are the Key Innovations Transforming the Exanthema Industry?
4. Which Region Is Leading the Exanthema Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.